李燕

[摘要] 目的 分析西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症的疗效。方法 按照随机抽样的方式，从该院2018年3月—2019年3月的脆性糖尿病伴高脂血症患者中，选取110例作为研究对象。对患者的临床资料进行整理，确定其完备性后，按照双色球分组的方式将其划分为两组——对照组（n=55）和观察组（n=55），前者采取单纯的预混胰岛素治疗，后者采取西格列汀联合预混胰岛素治疗。对两组患者治疗前、持续用药12周以后的血糖指标与血脂指标进行观察。结果 两组患者治疗前的血糖指标与血脂指标比较，差异无统计学意义（P>0.05）;在治疗后，观察组患者与对照组患者的血糖指标与血脂指标相比较，差异有统计学意义（P<0.05）。结论 西格列汀联合预混胰岛素治疗脆性糖尿病伴高脂血症的临床效果较好，能够对患者的血糖与血脂水平进行调整，且安全性较高，值得推广。

[关键词] 西格列汀;预混胰岛素;脆性糖尿病;高脂血症;疗效

[中图分类号] R587          [文献标识码] A          [文章编号] 1672-4062（2020）01（b）-0084-02

[Abstract] Objective To analyze the efficacy of sitagliptin combined with premixed insulin in the treatment of fragile diabetes with hyperlipidemia. Methods According to the random sampling method， 110 patients with brittle diabetes mellitus and hyperlipidemia from the hospital from March 2018 to March 2019  were selected as the research subjects. After the patient's clinical data were sorted out and their completeness was determined， they were divided into two groups according to the two-color ball grouping method： the control group （n=55） and the observation group （n=55）. The former adopted pure premixed insulin treatment， the latter was treated with sitagliptin in combination with premixed insulin. The blood glucose index and blood lipid index of the two groups of patients before and after 12 weeks of treatment were observed. Results There was no statistically significant difference in blood glucose index and blood lipid index between the two groups（P>0.05）. After treatment， the blood glucose index and blood lipid index of the observation group and the control group were statistically significant（P<0.05）. Conclusion Sitagliptin combined with premixed insulin is effective in the treatment of fragile diabetes with hyperlipidemia. It can adjust the blood glucose and blood lipid levels of patients， and it is safe and worth promoting.

[Key words] Sitagliptin; Premixed insulin; Fragile diabetes; Hyperlipidemia; Efficacy

随着当前社会环境的优化，人们的饮食条件在逐渐提升，这就使得各种代谢性疾病的發生率逐年上升。糖尿病作为临床相对常见的一种疾病，其多是因个体的胰岛素分泌存在异常所致。脆性糖尿病作为一种不稳定型糖尿病，在患病后患者会存在血糖波动较大、血糖难以控制、病情不稳定性较强、容易诱发其他并发症等临床症状[1]。且由于脆性糖尿病的存在，患者的免疫系统会受损，其他疾病的诱发可能性相对提高，因此，多数脆性糖尿病患者都伴随着其他疾病。高脂血症作为常见的一种伴随疾病，多表现为患者的体内脂质代谢紊乱，血脂水平异常[2]。这就……